(Q38558097)

4 September 2017

title

The two-century journey of Parkinson disease research (English)

1 reference

4 September 2017

1 reference

Serge Przedborski

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 March 2017

1 reference

Nature Reviews Neuroscience

4 September 2017

published in

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

251-259

1 reference

The history of Parkinson's disease: early clinical descriptions and neurological therapies

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkinson's disease: mechanisms and models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Postencephalitic parkinsonism--a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Advances in markers of prodromal Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PROGRESSIVE LENTICULAR DEGENERATION: A FAMILIAL NERVOUS DISEASE ASSOCIATED WITH CIRRHOSIS OF THE LIVER

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The brain-stem lesions in Parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Ageing and Parkinson's disease: substantia nigra regional selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Catechol compounds in rat tissues and in brains of different animals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

On the presence of 3-hydroxytyramine in brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Occurrence and distribution of dopamine in brain and other tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Distribution of catechol compounds in human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The medical treatment of Parkinson disease from James Parkinson to George Cotzias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Dopamine receptors: from structure to function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Cell-based therapies for Parkinson disease—past insights and future potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Pathological synchronization in Parkinson's disease: networks, models and treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Closed-loop deep brain stimulation is superior in ameliorating parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Functional neuroimaging in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Recent advances in the molecular biology of dopamine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Primate models of movement disorders of basal ganglia origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The functional anatomy of basal ganglia disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Neural mechanisms in disorders of movement.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Basal ganglia subcircuits distinctively encode the parsing and concatenation of action sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Complementary Contributions of Striatal Projection Pathways to Action Initiation and Execution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Dopamine Is Required for the Neural Representation and Control of Movement Vigor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Opponent and bidirectional control of movement velocity in the basal ganglia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Why don't we move faster? Parkinson's disease, movement vigor, and implicit motivation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial complex I deficiency in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondria: the next (neurode)generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Maternal inheritance in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkin and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PINK1-dependent recruitment of Parkin to mitochondria in mitophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

PINK1 is selectively stabilized on impaired mitochondria to activate Parkin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

A novel α-synuclein missense mutation in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

α-Synuclein in Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The many faces of α-synuclein: from structure and toxicity to therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the α-synuclein gene in early onset patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

alpha-Synuclein locus triplication causes Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Risk of Parkinson's disease among first-degree relatives: A community-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Advances in the genetics of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Association between early-onset Parkinson's disease and mutations in the parkin gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Age at onset of Parkinson disease and apolipoprotein E genotypes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Age at onset in two common neurodegenerative diseases is genetically controlled

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Parkinson disease in twins: an etiologic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Pathology of PD in monozygotic twins with a 20-year discordance interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Imputation of variants from the 1000 Genomes Project modestly improves known associations and can identify low-frequency variant-phenotype associations undetected by HapMap based imputation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Staging of brain pathology related to sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

The Central Nervous System and the Gut Microbiome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2017.25

RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis

31 March 2020

1 reference

12 December 2020

Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

1 reference

12 December 2020

Nigral and extranigral pathology in Parkinson's disease.

1 reference

12 December 2020

The occurrence, distribution and physiological role of catecholamines in the nervous system

1 reference

12 December 2020

A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy

1 reference

12 December 2020

Neuromelanin and Parkinson's disease

1 reference

12 December 2020

A common LRRK2 mutation in idiopathic Parkinson's disease

1 reference

12 December 2020

Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. (ISSN 0001-8724) Tokyo, October 1960;5:42-48

1 reference

12 December 2020

EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Astrocytes and Parkinson's disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRN.2017.25

1 reference

Dimensions Publication ID

4 September 2017

1084129768

0 references

1 reference